BrainScope

Bethesda, MarylandFounded 199011–50 employeesbrainscope.comLinkedIn

EEG and neural monitoring

BrainScope is a neurotechnology company that transforms EEG data into rapid, objective diagnostic insights for brain health and patient care. Its FDA-cleared point-of-care technology assesses head-injured patients for both brain bleeds and concussions while the company develops biomarkers for conditions including Alzheimer’s disease, stroke, ARIA, and concussion.

Visit brainscope.com ↗

Founded: 1990
Employees: 11–50

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

Recent highlights

BrainScope’s activity through September 2026 shows a shift from product development toward broader commercialization and clinical applications. On Jun 11, 2025, the company announced an advanced deep-learning platform intended to expand brain-health insights, alongside a board expansion. Matt Adams became chief executive officer and a board member on Nov 4, 2025, succeeding Laurie Silver. BrainScope then added six neuroscience leaders to its Advisory Board on Jan 13, 2026, supporting expansion into AI-driven neurodiagnostics and additional clinical indications. A February 2026 publication highlighted an EEG-based biomarker that predicted dementia risk up to seven years before initial diagnosis, extending the company’s research narrative beyond acute head injury. On May 4, 2026, David Wingate joined as Vice President of Sales and Commercial Operations, with a mandate to lead commercial strategy and accelerate adoption of BrainScope’s AI-enabled assessments. The sequence of leadership, advisory, platform, and biomarker developments suggests that BrainScope is building commercial infrastructure around a platform initially established for point-of-care concussion and intracranial injury assessment.

Market position

BrainScope operates at the intersection of neurodiagnostics, medical devices, digital signal processing, and clinical decision support. Its stated differentiation is an FDA-cleared, portable, EEG-based platform that provides radiation-free assessments for brain injury at the point of care. The product portfolio includes the Structural Injury Classifier for brain-bleed likelihood, the Brain Function Index for impairment, the Concussion Index for patients aged 13 to 25, and a digitized pediatric PECARN decision tool. This gives BrainScope a narrower but more clinically integrated position than general-purpose EEG vendors or software-only digital health companies. The company also claims more than 15 years of experience converting EEG signals into actionable insights and is extending its platform toward dementia, stroke, ARIA, drug development, and consumer health. Its competitive challenge is clear nonetheless: converting regulatory clearance and proprietary signal-processing capabilities into routine clinical adoption, reimbursement support, and evidence across additional indications.

Growth & opportunities

BrainScope’s funding history reflects a long medical-device development cycle rather than a conventional rapid-growth software trajectory. The company has an aggregate funding total of $87.1 million across 13 recorded rounds, including a $16 million venture round in 2017, a $35 million debt-financing transaction in 2021, and a Series B announced on Sep 19, 2023 with no public amount. Earlier financing included $16.5 million in debt financing in 2015, a $10 million convertible note in 2013, and a $2.4 million venture round in 2010. The main recent inflection points are operational and technological. In June 2025, BrainScope introduced an advanced deep-learning platform; in November 2025, Matt Adams became CEO; and in January and May 2026, the company expanded its advisory and commercial leadership. The February 2026 dementia-biomarker publication further broadened the potential use case beyond acute traumatic brain injury. With an employee range of 11–50, growth appears focused on specialized commercialization, clinical validation, and indication expansion rather than large-scale headcount acceleration.

Written by reccy's AI from company sites, press and funding records · updated Sep 2026

What makes BrainScope distinct

reccy insights

What makes BrainScope distinct

01Developed the first FDA-cleared AI and machine-learning medical device in neurology.
02Offers point-of-care technology for objectively assessing both brain bleeds and concussions.
03Delivers rapid, radiation-free biomarkers that may reduce unnecessary head CTs and emergency-department stays.
04Has more than 15 years of experience converting EEG signals into actionable clinical insights.
05Extends its platform across acute care, drug development, and consumer-health applications.

Technology & products4

Technology & products

BrainScope Structural Injury Classifier (SIC)
An FDA-cleared device that assesses the likelihood of brain bleed in adults with mild traumatic brain injury at the time of injury.
BrainScope Brain Function Index (BFI)
A tool that measures brain function impairment to assist in evaluating concussion severity in adults at the time of injury.
BrainScope Concussion Index (CI)
A device-based assessment for initial concussion evaluation in individuals aged 13 to 25 years.
Digitized PECARN Decision Rule
A digital tool to aid clinicians in determining the need for head CT scans in patients aged 2 to 17 years after head injury.

Show all 4 products

+ 1 more: Digitized PECARN Decision Rule

Recent updates4

Launches, partnerships and team changes from press coverage

May 5, 2026Team change
BrainScope appointed David Wingate as Vice President of Sales and Commercial Operations to lead commercial strategy and accelerate adoption of its AI-enabled brain health assessment technologies.
biospace.com
Jan 13, 2026Team change
BrainScope appointed six neuroscience leaders to its Advisory Board to support its expansion in AI-driven neurodiagnostics and new clinical indications.
pharmiweb.com
Nov 4, 2025Team change
BrainScope appointed Matt Adams as Chief Executive Officer and board member, succeeding Laurie Silver.
businesswire.com
Jun 11, 2025Team change
BrainScope expanded its board and launched an advanced deep-learning platform to enhance brain-health insights.
businesswire.com

Show all 4 updates

Similar companies

Show all 6 companies

About BrainScope

Products: BrainScope Structural Injury Classifier (SIC), BrainScope Brain Function Index (BFI), BrainScope Concussion Index (CI), Digitized PECARN Decision Rule
Leadership: Leslie S Prichep, Chief Scientific OfficerKim Bracuti, Chief Financial OfficerAngad Singh, Chief Technology OfficerLaurie Silver, President
Focus areas: Neurotechnology, medical devices, digital health, AI/ML, diagnostics, EEG, brain health, clinical decision support
Headquarters: Bethesda, Maryland
Founded: 1990
Employees: 11–50
Patents granted: 33 (Crunchbase)
Trademarks: 3